Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - influenza virus (sh) a/brisbane/1/2018 x-311(h3n2); influenza virus (sh) a/michigan/45/2015 x-275 (h1n1); influenza virus (sh) b/maryland/15/2016 bx-69a; influenza virus (sh) b/phuket/3073/2013 - injection, suspension - influenza virus (sh) a/brisbane/1/2018 x-311(h3n2) 7.5 mcg/0.25 ml; influenza virus (sh) a/michigan/45/2015 x-275 (h1n1) 7.5 mcg/0.25 ml; influenza virus (sh) b/maryland/15/2016 bx-69a 7.5 mcg/0.25 ml; influenza virus (sh) b/phuket/3073/2013 7.5 mcg/0.25 ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - influenza virus (sh) a/brisbane/1/2018 x-311 (h3n2); influenza virus (sh) a/michigan/45/2015 x-275 (h1n1); influenza virus (sh) b/maryland/15/2016 bx-69a; influenza virus (sh) b/phuket/3073/2013 - injection, suspension - influenza virus (sh) a/brisbane/1/2018 x-311 (h3n2) 15 mcg/0.5 ml; influenza virus (sh) a/michigan/45/2015 x-275 (h1n1) 15 mcg/0.5 ml; influenza virus (sh) b/maryland/15/2016 bx-69a 15 mcg/0.5 ml; influenza virus (sh) b/phuket/3073/2013 15 mcg/0.5 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238)); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/thailand/8/2022, ivr-237)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like strain (b/phuket/3073/2013, wild type)) - suspension for injection - 0.5 ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238)) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/thailand/8/2022, ivr-237)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like strain (b/phuket/3073/2013, wild type)) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra is indicated in adults and children from 6 months of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)); influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018 (x-311)); influenza virus b/phuket/3073/2013 - like strain 15ug ( b/phuket/3073/2013 (bvr-1b)) - suspension for injection - 45 mcg/0.5ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)) influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018 (x-311)) influenza virus b/phuket/3073/2013 - like strain 15ug ( b/phuket/3073/2013 (bvr-1b)) excipient: calcium chloride dihydrate citric acid monohydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride sodium citrate dihydrate sorbitan trioleate squalene water for injection - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases). the use of fluad should be based on official recommendations.

Israel - English - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

European Union - English - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccines - prophylaxis of influenza caused by a(h1n1)v 2009 virus.celvapan should be used in accordance with official guidance.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) - suspension for injection - 60 mcg - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) excipient: octoxinol 9 phosphate buffered saline - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri is indicated for use in adults and children 6 months and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin, quantity: 60 microgram - injection, suspension - excipient ingredients: octoxinol 9; monobasic sodium phosphate; water for injections; dibasic sodium phosphate; sodium chloride - fluzone high-dose quadrivalent (qiv) is indicated for active immunisation for the prevention of influenza disease. fluzone high-dose quadrivalent is indicated for use in persons 60 years of age and older., the use of fluzone high-dose quadrivalent (qiv) should be based on official recommendations., see section 5.1 clinical trials for information on the effects on influenza associated complications.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -